Matt Hewitt
Stock Analyst at Craig-Hallum
(2.73)
# 2,085
Out of 5,050 analysts
40
Total ratings
54.05%
Success rate
4.2%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $17.13 | +110.16% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.74 | +78.04% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.67 | +124.72% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.93 | +23.41% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $35.68 | +79.37% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $1.16 | +762.07% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $17.78 | +68.73% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.44 | +386.11% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $142.82 | +40.04% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $1.38 | +624.64% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.53 | +298.41% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.64 | +62,605.75% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $17.13
Upside: +110.16%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.74
Upside: +78.04%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.67
Upside: +124.72%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.93
Upside: +23.41%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $35.68
Upside: +79.37%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.16
Upside: +762.07%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $17.78
Upside: +68.73%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $142.82
Upside: +40.04%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.38
Upside: +624.64%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.53
Upside: +298.41%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.64
Upside: +62,605.75%